Please Wait.....
Report
Global Thyroid Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 419 Pages I Data Bridge Market Research
The global thyroid cancer diagnostics market is projected to register a substantial CAGR of 5.7% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation:
Global Thyroid Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, Others), Cancer type (Papillary Carcinoma, Follicular Carcinoma, Others), Stages (Stage I, Stage II, Stage III, Stage IV), Age Group ( 30-65, 65 and above, 21-29, Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the global thyroid cancer diagnostics market are:
- Rising incidence and prevalence of thyroid nodules & cancer
- Rising thyroid cancer diagnostic tests rise in product approvals
- Rise in healthcare expenditure for cancer diagnosis and treatment
- Rising awareness towards thyroid cancer
Market Players:
Some of the major players operating in the global thyroid cancer diagnostics market are:
- Canon Inc.
- FUJIFILM Holdings Corporation
- F. Hoffmann-La Roche Ltd
- Quest Diagnostics Incorporated
- Illumina
- Koninklijke Philips N.V.
- Thermo Fisher Scientific Inc.
- Siemens Healthcare GmbH
- Abbott
- General Electric Company
- BD
- QIAGEN
- DIASORIN S.P.A.
- Merck KGaA
- Hologic
- Myriad Genetics Inc.
- BIOMERIEUX
- FONAR Corp.
- Time Medical Holding.
- PlexBio.
- MinFound Medical Systems Co., Ltd
- Medonica Co. LTD
- Beijing O&D Biotech Co., Ltd.
- SternMed GmbH
TABLE OF CONTENTS
1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.3 OVERVIEW OF THE GLOBAL THYROID CANCER DIAGNOSTICS MARKET 47
1.4 LIMITATIONS 49
1.5 MARKETS COVERED 49
2 MARKET SEGMENTATION 52
2.1 MARKETS COVERED 52
2.2 GEOGRAPHICAL SCOPE 53
2.3 YEARS CONSIDERED FOR THE STUDY 54
2.4 CURRENCY AND PRICING 54
2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
2.6 MULTIVARIATE MODELLING 58
2.7 PRODUCT TYPE LIFELINE CURVE 58
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
2.9 DBMR MARKET POSITION GRID 60
2.10 MARKET TESTING TYPE COVERAGE GRID 62
2.11 VENDOR SHARE ANALYSIS 63
2.12 SECONDARY SOURCES 64
2.13 ASSUMPTIONS 64
3 EXECUTIVE SUMMARY 65
4 PREMIUM INSIGHTS 68
4.1 PESTEL ANALYSIS 71
4.2 PORTER'S FIVE FORCES 72
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 73
5 EPIDEMIOLOGY 74
6 REGULATORY FRAMEWORK OF THE GLOBAL THYROID CANCER DIAGNOSTICS MARKET 75
6.1 REGULATORY SCENARIO IN THE U.S. 75
6.2 REGULATORY SCENARIO IN AUSTRALIA 76
6.3 REGULATORY SCENARIO IN JAPAN 76
6.4 REGULATORY SCENARIO IN CHINA 76
7 MARKET OVERVIEW 77
7.1 DRIVERS 79
7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER 79
7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS 79
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 80
7.1.4 RISING AWARENESS TOWARDS THYROID CANCER 80
7.2 RESTRAINTS 81
7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE 81
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 82
7.3 OPPORTUNITIES 82
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 82
7.3.2 RISING OBESE POPULATION 83
7.4 CHALLENGES 83
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 83
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 84
8 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 85
8.1 OVERVIEW 86
8.2 INSTRUMENTS 89
8.2.1 PATHOLOGY BASED INSTRUMENTS 90
8.2.1.1 PCR INSTRUMENTS 90
8.2.1.2 SLIDE STAINING SYSTEMS 90
8.2.1.3 TISSUE PROCESSING SYSTEMS 90
8.2.1.4 CELL PROCESSORS 91
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 91
8.2.2 IMAGING INSTRUMENTS 91
8.2.2.1 ULTRASOUND SYSTEMS 91
8.2.2.2 CT SYSTEMS 91
8.2.2.3 MRI SYSTEMS 91
8.2.2.4 OTHERS 91
8.2.3 BIOPSY INSTRUMENTS 92
8.2.3.1 NEEDLE BIOPSY 92
8.2.3.2 ENDOSCOPIC BIOPSY 92
8.2.3.3 CORE BIOPSY 92
8.2.3.4 OTHERS 92
8.2.4 OTHERS 92
8.3 CONSUMABLES & ACCESSORIES 93
8.3.1 KITS 94
8.3.1.1 PCR KITS 94
8.3.1.2 DNA POLYMERASE KITS 94
8.3.1.3 NUCLEIC ACID ISOLATION KITS 94
8.3.1.4 OTHERS 94
8.3.2 REAGENTS 95
8.3.2.1 ASSAYS 95
8.3.2.2 BUFFERS 95
8.3.2.3 PRIMERS 95
8.3.2.4 OTHERS 95
8.3.3 PROBES 95
8.3.4 OTHER CONSUMABLES 95
9 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE 96
9.1 OVERVIEW 97
9.2 IMAGING TEST 100
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 101
9.2.2 MRI 101
9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 101
9.2.4 OTHERS 101
9.3 BLOOD TEST 102
9.3.1 BLOOD CHEMISTRY TESTS 103
9.3.2 COMPLETE BLOOD COUNT (CBC) 103
9.3.3 OTHERS 103
9.4 BIOPSY 103
9.4.1 NEEDLE BIOPSY 104
9.4.2 BRONCHOSCOPY BIOPSY 104
9.4.3 CORE BIOPSY 104
9.4.4 OTHERS 104
9.5 OTHERS 105
10 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 106
10.1 OVERVIEW 107
10.2 PAPILLARY CARCINOMA 110
10.3 FOLLICULAR CARCINOMA 111
10.4 OTHERS 112
11 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY STAGES 113
11.1 OVERVIEW 114
11.2 STAGE I 117
11.3 STAGE II 118
11.4 STAGE III 119
11.5 STAGE IV 120
12 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP 121
12.1 OVERVIEW 122
12.2 30-65 125
12.3 65 AND ABOVE 126
12.4 21-29 127
12.5 BELOW 21 128
13 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY END USER 129
13.1 OVERVIEW 130
13.2 HOSPITALS 133
13.3 ASSOCIATED LABS 134
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 134
13.5 DIAGNOSTIC IMAGING CENTERS 135
13.6 CANCER RESEARCH INSTITUTES 136
13.7 OTHERS 137
14 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 138
14.1 OVERVIEW 139
14.2 DIRECT TENDER 142
14.3 RETAIL SALES 143
15 GLOBAL THYROID CANCER DIAGNOSTICS MARKET, BY REGION 144
15.1 OVERVIEW 145
15.2 NORTH AMERICA 151
15.2.1 U.S. 161
15.2.2 CANADA 166
15.2.3 MEXICO 171
15.3 EUROPE 176
15.3.1 GERMANY 186
15.3.2 U.K. 191
15.3.3 ITALY 196
15.3.4 FRANCE 201
15.3.5 SPAIN 206
15.3.6 RUSSIA 211
15.3.7 SWITZERLAND 216
15.3.8 TURKEY 221
15.3.9 BELGIUM 226
15.3.10 NETHERLANDS 231
15.3.11 REST OF EUROPE 236
15.4 ASIA-PACIFIC 237
15.4.1 JAPAN 247
15.4.2 CHINA 252
15.4.3 SOUTH KOREA 258
15.4.4 INDIA 263
15.4.5 THAILAND 268
15.4.6 SINGAPORE 273
15.4.7 INDONESIA 278
15.4.8 MALAYSIA 283
15.4.9 PHILIPPINES 288
15.4.10 AUSTRALIA 294
15.4.11 VIETNAM 299
15.4.12 REST OF ASIA-PACIFIC 304
15.5 SOUTH AMERICA 305
15.5.1 BRAZIL 316
15.5.2 ARGENTINA 321
15.5.3 REST OF SOUTH AMERICA 327
15.6 MIDDLE EAST AND AFRICA 328
15.6.1 SAUDI ARABIA 339
15.6.2 U.A.E. 344
15.6.3 SOUTH AFRICA 349
15.6.4 EGYPT 355
15.6.5 ISRAEL 360
15.6.6 REST OF MIDDLE EAST AND AFRICA 365
16 GLOBAL THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 366
16.1 COMPANY SHARE ANALYSIS: GLOBAL 366
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 367
16.3 COMPANY SHARE ANALYSIS: EUROPE 368
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 369
17 SWOT ANALYSIS 370
18 COMPANY PROFILE 371
18.1 CANON INC. 371
18.1.1 COMPANY SNAPSHOT 371
18.1.2 COMPANY SHARE ANALYSIS 371
18.1.3 PRODUCT PORTFOLIO 372
18.1.4 RECENT DEVELOPMENTS 372
18.2 FUJIFILM CORPORATION 373
18.2.1 COMPANY SNAPSHOT 373
18.2.2 REVENUE ANALYSIS 373
18.2.3 COMPANY SHARE ANALYSIS 374
18.2.4 PRODUCT PORTFOLIO 374
18.2.5 RECENT DEVELOPMENT 374
18.3 F. HOFFMANN-LA ROCHE LTD 375
18.3.1 COMPANY SNAPSHOT 375
18.3.2 REVENUE ANALYSIS 375
18.3.3 COMPANY SHARE ANALYSIS 376
18.3.4 PRODUCT PORTFOLIO 376
18.3.5 RECENT DEVELOPMENT 376
18.4 QUEST DIAGNOSTICS INCORPORATED 377
18.4.1 COMPANY SNAPSHOT 377
18.4.2 REVENUE ANALYSIS 377
18.4.3 COMPANY SHARE ANALYSIS 378
18.4.4 PRODUCT PORTFOLIO 378
18.4.5 RECENT DEVELOPMENTS 378
18.5 ILLUMINA, INC. 380
18.5.1 COMPANY SNAPSHOT 380
18.5.2 REVENUE ANALYSIS 380
18.5.3 COMPANY SHARE ANALYSIS 381
18.5.4 PRODUCT PORTFOLIO 381
18.5.5 RECENT DEVELOPMENT 381
18.6 ABBOTT 382
18.6.1 COMPANY SNAPSHOT 382
18.6.2 REVENUE ANALYSIS 382
18.6.3 PRODUCT PORTFOLIO 383
18.6.4 RECENT DEVELOPMENT 383
18.7 BD 384
18.7.1 COMPANY SNAPSHOT 384
18.7.2 REVENUE ANALYSIS 384
18.7.3 PRODUCT PORTFOLIO 385
18.7.4 RECENT DEVELOPMENT 385
18.8 BEIJING O&D BIOTECH CO., LTD. 386
18.8.1 COMPANY SNAPSHOT 386
18.8.2 PRODUCT PORTFOLIO 386
18.8.3 RECENT DEVELOPMENTS 386
18.9 BIOMERIEUX SA 387
18.9.1 COMPANY SNAPSHOT 387
18.9.2 REVENUE ANALYSIS 387
18.9.3 PRODUCT PORTFOLIO 388
18.9.4 RECENT DEVELOPMENTS 388
18.10 DIASORIN S.P.A. 389
18.10.1 COMPANY SNAPSHOT 389
18.10.2 REVENUE ANALYSIS 389
18.10.3 PRODUCT PORTFOLIO 390
18.10.4 RECENT DEVELOPMENT 390
18.11 FONAR CORP. 391
18.11.1 COMPANY SNAPSHOT 391
18.11.2 REVENUE ANALYSIS 391
18.11.3 PRODUCT PORTFOLIO 392
18.11.4 RECENT DEVELOPMENTS 392
18.12 GENERAL ELECTRIC 393
18.12.1 COMPANY SNAPSHOT 393
18.12.2 REVENUE ANALYSIS 393
18.12.3 PRODUCT PORTFOLIO 394
18.12.4 RECENT DEVELOPMENTS 394
18.13 HOLOGIC INC. 395
18.13.1 COMPANY SNAPSHOT 395
18.13.2 REVENUE ANALYSIS 395
18.13.3 PRODUCT PORTFOLIO 396
18.13.4 RECENT DEVELOPMENT 396
18.14 KONINKLIJKE PHILIPS N.V. 397
18.14.1 COMPANY SNAPSHOT 397
18.14.2 REVENUE ANALYSIS 397
18.14.3 PRODUCT PORTFOLIO 398
18.14.4 RECENT DEVELOPMENT 398
18.15 MERCK KGAA. 399
18.15.1 COMPANY SNAPSHOT 399
18.15.2 REVENUE ANALYSIS 399
18.15.3 PRODUCT PORTFOLIO 400
18.15.4 RECENT DEVELOPMENT 400
18.16 MEDONICA CO. LTD 401
18.16.1 COMPANY SNAPSHOT 401
18.16.2 PRODUCT PORTFOLIO 401
18.16.3 RECENT DEVELOPMENT 401
18.17 MINFOUND MEDICAL SYSTEMS CO. LTD 402
18.17.1 COMPANY SNAPSHOT 402
18.17.2 PRODUCT PORTFOLIO 402
18.17.3 RECENT DEVELOPMENTS 403
18.18 MYRIAD GENETICS, INC. 404
18.18.1 COMPANY SNAPSHOT 404
18.18.2 REVENUE ANALYSIS 404
18.18.3 PRODUCT PORTFOLIO 405
18.18.4 RECENT DEVELOPMENTS 405
18.19 PLEXBIO. 406
18.19.1 COMPANY SNAPSHOT 406
18.19.2 PRODUCT PORTFOLIO 406
18.19.3 RECENT DEVELOPMENTS 406
18.20 QIAGEN 407
18.20.1 COMPANY SNAPSHOT 407
18.20.2 REVENUE ANALYSIS 407
18.20.3 PRODUCT PORTFOLIO 408
18.20.4 RECENT DEVELOPMENT 408
18.21 STERNMED GMBH 409
18.21.1 COMPANY SNAPSHOT 409
18.21.2 PRODUCT PORTFOLIO 409
18.21.3 RECENT DEVELOPMENTS 409
18.22 SIEMENS HEALTHCARE GMBH 410
18.22.1 COMPANY SNAPSHOT 410
18.22.2 REVENUE ANALYSIS 410
18.22.3 PRODUCT PORTFOLIO 411
18.22.4 RECENT DEVELOPMENT 411
18.23 TIME MEDICAL HOLDING. 412
18.23.1 COMPANY SNAPSHOT 412
18.23.2 PRODUCT PORTFOLIO 412
18.23.3 RECENT DEVELOPMENT 412
18.24 THERMO FISHER SCIENTIFIC INC. 413
18.24.1 COMPANY SNAPSHOT 413
18.24.2 REVENUE ANALYSIS 413
18.24.3 PRODUCT PORTFOLIO 414
18.24.4 RECENT DEVELOPMENT 414
19 QUESTIONNAIRE 415
20 RELATED REPORTS 419
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security